ANI Pharmaceuticals (NASDAQ:ANIP) Price Target Raised to $115.00 at Guggenheim

ANI Pharmaceuticals (NASDAQ:ANIP) had its target price hoisted by research analysts at Guggenheim from $114.00 to $115.00 in a report released on Monday,Benzinga reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Guggenheim’s target price points to a potential upside of 30.40% from the company’s previous close.

A number of other brokerages have also recently commented on ANIP. HC Wainwright boosted their target price on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 21st. Weiss Ratings raised ANI Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 24th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Finally, JPMorgan Chase & Co. lifted their price target on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Buy” and a consensus target price of $99.29.

ANI Pharmaceuticals Trading Down 2.5%

ANI Pharmaceuticals stock traded down $2.24 during mid-day trading on Monday, reaching $88.19. 83,866 shares of the company traded hands, compared to its average volume of 367,885. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96. ANI Pharmaceuticals has a 52-week low of $52.50 and a 52-week high of $99.50. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -114.91 and a beta of 0.54. The firm’s 50 day moving average price is $93.58 and its 200 day moving average price is $77.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same quarter in the previous year, the firm posted $1.34 EPS. The company’s revenue for the quarter was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Jeanne Thoma sold 21,540 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $89.15, for a total transaction of $1,920,291.00. Following the transaction, the director owned 23,405 shares in the company, valued at approximately $2,086,555.75. This trade represents a 47.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Nikhil Lalwani sold 56,960 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total transaction of $4,894,572.80. Following the completion of the sale, the chief executive officer directly owned 411,219 shares of the company’s stock, valued at approximately $35,336,048.67. This trade represents a 12.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 413,830 shares of company stock valued at $36,505,378 over the last 90 days. 11.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

Large investors have recently bought and sold shares of the business. Advisors Asset Management Inc. purchased a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. boosted its position in ANI Pharmaceuticals by 202.6% during the third quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock valued at $32,000 after purchasing an additional 237 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its stake in ANI Pharmaceuticals by 4,636.4% in the second quarter. Caitong International Asset Management Co. Ltd now owns 521 shares of the specialty pharmaceutical company’s stock valued at $34,000 after purchasing an additional 510 shares during the last quarter. Newbridge Financial Services Group Inc. grew its stake in ANI Pharmaceuticals by 200.0% in the second quarter. Newbridge Financial Services Group Inc. now owns 600 shares of the specialty pharmaceutical company’s stock valued at $39,000 after purchasing an additional 400 shares during the last quarter. Finally, State of Wyoming bought a new position in ANI Pharmaceuticals in the second quarter worth about $50,000. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.